168 related articles for article (PubMed ID: 35524445)
21. Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment.
Fofi L; Altamura C; Fiorentini G; Brunelli N; Marcosano M; Barbanti P; Vernieri F
Headache; 2022 Oct; 62(9):1143-1147. PubMed ID: 36205100
[TBL] [Abstract][Full Text] [Related]
22. Faster Improvement in Migraine Pain Intensity and Migraine-Related Disability at Early Time Points with AVP-825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the COMPASS Study.
Lipton RB; McGinley JS; Shulman KJ; Wirth RJ; Buse DC
Headache; 2017 Nov; 57(10):1570-1582. PubMed ID: 28880380
[TBL] [Abstract][Full Text] [Related]
23. Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews.
Derry CJ; Derry S; Moore RA
Cochrane Database Syst Rev; 2014 May; 2014(5):CD009108. PubMed ID: 24865446
[TBL] [Abstract][Full Text] [Related]
24. Predictors of First-Line Treatment Success in Children and Adolescents Visiting an Infusion Center for Acute Migraine.
Orr SL; Kabbouche MA; Horn PS; O'Brien HL; Kacperski J; LeCates S; White S; Weberding J; Miller MN; Powers SW; Hershey AD
Headache; 2018 Sep; 58(8):1194-1202. PubMed ID: 29926909
[TBL] [Abstract][Full Text] [Related]
25. Occipital Nerve Stimulation for Refractory Chronic Migraine: Results of a Long-Term Prospective Study.
Rodrigo D; Acin P; Bermejo P
Pain Physician; 2017; 20(1):E151-E159. PubMed ID: 28072807
[TBL] [Abstract][Full Text] [Related]
26. Patient and caregiver preferences on treatment attributes for atopic dermatitis.
Ervin C; Crawford R; Evans E; Feldman SR; Zeichner J; Zielinski MA; Cappelleri JC; DiBonaventura M; Takiya L; Myers DE
J Dermatolog Treat; 2022 Jun; 33(4):2225-2233. PubMed ID: 34264145
[TBL] [Abstract][Full Text] [Related]
27. Pain among children and adolescents: restrictions in daily living and triggering factors.
Roth-Isigkeit A; Thyen U; Stöven H; Schwarzenberger J; Schmucker P
Pediatrics; 2005 Feb; 115(2):e152-62. PubMed ID: 15687423
[TBL] [Abstract][Full Text] [Related]
28. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.
Oskoui M; Pringsheim T; Billinghurst L; Potrebic S; Gersz EM; Gloss D; Holler-Managan Y; Leininger E; Licking N; Mack K; Powers SW; Sowell M; Victorio MC; Yonker M; Zanitsch H; Hershey AD
Neurology; 2019 Sep; 93(11):500-509. PubMed ID: 31413170
[TBL] [Abstract][Full Text] [Related]
29. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks.
Tepper SJ; Cady RK; Silberstein S; Messina J; Mahmoud RA; Djupesland PG; Shin P; Siffert J
Headache; 2015 May; 55(5):621-35. PubMed ID: 25941016
[TBL] [Abstract][Full Text] [Related]
30. Multimodal Assessment of Medication Adherence Among Youth With Migraine: An Ancillary Study of the CHAMP Trial.
Reidy BL; Powers SW; Coffey CS; Chamberlin LA; Ecklund DJ; Klingner EA; Yankey JW; Korbee LL; Porter LL; Peugh J; Kabbouche MA; Kacperski J; Hershey AD;
J Pediatr Psychol; 2022 Apr; 47(4):376-387. PubMed ID: 34865085
[TBL] [Abstract][Full Text] [Related]
31. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures.
Silberstein S; Lipton R; Dodick D; Freitag F; Mathew N; Brandes J; Bigal M; Ascher S; Morein J; Wright P; Greenberg S; Hulihan J
Headache; 2009 Sep; 49(8):1153-62. PubMed ID: 19719543
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of green light exposure on headache frequency and quality of life in migraine patients: A preliminary one-way cross-over clinical trial.
Martin LF; Patwardhan AM; Jain SV; Salloum MM; Freeman J; Khanna R; Gannala P; Goel V; Jones-MacFarland FN; Killgore WD; Porreca F; Ibrahim MM
Cephalalgia; 2021 Feb; 41(2):135-147. PubMed ID: 32903062
[TBL] [Abstract][Full Text] [Related]
33. Practice guideline update summary: Pharmacologic treatment for pediatric migraine prevention: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.
Oskoui M; Pringsheim T; Billinghurst L; Potrebic S; Gersz EM; Gloss D; Holler-Managan Y; Leininger E; Licking N; Mack K; Powers SW; Sowell M; Cristina Victorio M; Yonker M; Zanitsch H; Hershey AD
Headache; 2019 Sep; 59(8):1144-1157. PubMed ID: 31529477
[TBL] [Abstract][Full Text] [Related]
34. Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study.
Bell CF; Foley KA; Barlas S; Solomon G; Hu XH
Clin Ther; 2006 Jun; 28(6):872-80. PubMed ID: 16860170
[TBL] [Abstract][Full Text] [Related]
35. Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial.
Ailani J; McAllister P; Winner PK; Chakhava G; Krog Josiassen M; Lindsten A; Sperling B; Ettrup A; Cady R
BMC Neurol; 2022 Jun; 22(1):205. PubMed ID: 35659622
[TBL] [Abstract][Full Text] [Related]
36. Phase 3 randomized, double-blind, sham-controlled Trial of e-TNS for the Acute treatment of Migraine (TEAM).
Kuruvilla DE; Mann JI; Tepper SJ; Starling AJ; Panza G; Johnson MAL
Sci Rep; 2022 Mar; 12(1):5110. PubMed ID: 35332216
[TBL] [Abstract][Full Text] [Related]
37. An observational study of fixed-dose Tanacetum parthenium nutraceutical preparation for prophylaxis of pediatric headache.
Moscano F; Guiducci M; Maltoni L; Striano P; Ledda MG; Zoroddu F; Raucci U; Villa MP; Parisi P
Ital J Pediatr; 2019 Mar; 45(1):36. PubMed ID: 30871574
[TBL] [Abstract][Full Text] [Related]
38. Galcanezumab effect on "whole pain burden" and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience.
Silvestro M; Tessitore A; Orologio I; De Micco R; Tartaglione L; Trojsi F; Tedeschi G; Russo A
J Headache Pain; 2022 Jun; 23(1):69. PubMed ID: 35698070
[TBL] [Abstract][Full Text] [Related]
39. Intervention for Sleep and Pain in Youth (ISPY-RCT): protocol for a two-phase randomized controlled trial of sequenced cognitive-behavioral therapy for insomnia and pain management in adolescents with migraine.
Law EF; Ritterband L; Zhou C; Palermo TM
Trials; 2023 Jan; 24(1):25. PubMed ID: 36635741
[TBL] [Abstract][Full Text] [Related]
40. Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies.
Ashina M; Vasudeva R; Jin L; Lombard L; Gray E; Doty EG; Yunes-Medina L; Kinchen KS; Tassorelli C
Headache; 2019 Nov; 59(10):1788-1801. PubMed ID: 31529622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
